Another recent study showed that Baricitinib, a JAK inhibitor blocking central inflammatory signaling pathways decreases systemic inflammation biomarkers, such as IL-6, CRP, as well as adiponectin, in rheumatoid arthritis patients33. This evidence concerns the gene ADIPOQ and rheumatoid arthritis.